December 19, 2014

Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States

learn more
December 18, 2014

Novocure to Present at the 33rd Annual J.P. Morgan Healthcare Conference

learn more
December 2, 2014

Novocure Announces FDA Approval of an IDE Supplement Allowing All Control Patients in its Phase III Trial in Newly Diagnosed GBM to Cross Over to Receive Tumor Treating Fields

learn more
December 1, 2014

Interim Analysis of Novocure’s Phase III Trial in Newly Diagnosed Glioblastoma to be Presented at Japan Society For Neuro-Oncology 2014

learn more
November 15, 2014

Novocure Announces the EF-14 Phase III Clinical Trial of Tumor Treating Fields in Patients with Newly Diagnosed Glioblastoma has been Terminated at the Interim Analysis due to Early Success

learn more
November 11, 2014

Novocure Announces Optune as the New Name for the NovoTTF-100A System

learn more
November 11, 2014

Novocure Announces the Presentation of New Data at the 19th Annual Society of Neuro-Oncology Meeting

learn more
October 30, 2014

Novocure Enrolls First Patient in a Pilot Study of Tumor Treating Fields Together with Paclitaxel for the Treatment of Recurrent Ovarian Cancer

learn more
October 29, 2014

Novocure Announces Publication of a NovoTTF Therapy Supplement in Seminars in Oncology including Analyses of its U.S. Commercial Patient Registry Dataset (PRiDe)

learn more
September 25, 2014

Novocure™ Announces Recurrent Glioblastoma Patient Registry Dataset (PRiDe) to be Presented at ESMO and EANO 2014

learn more